Compare VCEL & EAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VCEL | EAD |
|---|---|---|
| Founded | 1989 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 377.0M |
| IPO Year | 1996 | N/A |
| Metric | VCEL | EAD |
|---|---|---|
| Price | $39.49 | $5.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $60.57 | N/A |
| AVG Volume (30 Days) | ★ 397.9K | 249.0K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.91% |
| EPS Growth | ★ 60.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $276,259,000.00 | N/A |
| Revenue This Year | $21.71 | N/A |
| Revenue Next Year | $16.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.45 | N/A |
| 52 Week Low | $28.95 | $5.96 |
| 52 Week High | $49.32 | $7.06 |
| Indicator | VCEL | EAD |
|---|---|---|
| Relative Strength Index (RSI) | 47.72 | 31.36 |
| Support Level | $37.78 | N/A |
| Resistance Level | $41.12 | $6.44 |
| Average True Range (ATR) | 1.17 | 0.07 |
| MACD | 0.26 | -0.01 |
| Stochastic Oscillator | 69.65 | 28.57 |
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Allspring Income Opportunities Fund is a diversified closed-end management investment company. The Fund seeks a high level of current income. Capital appreciation is a secondary objective. The fund has single operating segment.